Medicare will start covering obesity drugs for some patients for the first time starting mid-2026. Certain Medicare patients will pay a copay of $50 per month for all approved uses of injectable and oral GLP-1 drugs, including diabetes and obesity treatment. Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approvals, will be $149 per month for everyone getting them through Medicare, Medicaid or TrumpRx.
- Great news for those who will be eligible!
Starting doses of existing injections like Novo’s Wegovy and Lilly’s Zepbound will be $350 per month on TrumpRX, but will “trend down” to $245 per month over a two-year period.
Still too much for a starting dose. This makes me think that this will only drive more people to compound and grey when the people they know who are eligible for Medicare coverage start getting their meds.